Search Results for "cobicistat"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cobicistat. Results 1 to 3 of 3 total matches.
See also: Stribild
Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
chlorpheniramine
chlorpromazine
cimetidine
clobazam
clomipramine
cobicistat
darifenacin
darunavir ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30 doi:10.58347/tml.2023.1669g | Show Introduction Hide Introduction
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate Increased tenofovir serum concentrations ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
,
such as ritonavir, cobicistat, or clarithromycin, can
increase serum concentrations of methadone,
and inducers ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction